- Home
- HGTY vs ELVN Comparison
HGTY vs ELVN Comparison
Compare HGTY & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HGTY | ELVN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HGTY | ELVN |
|---|---|---|
| Price | $12.00 | $28.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.00 | ★ $41.00 |
| AVG Volume (30 Days) | 112.2K | ★ 1.3M |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 241.11 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,360,017,000.00 | N/A |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.99 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $8.03 | $13.30 |
| 52 Week High | $14.00 | $30.22 |
Technical Indicators
Market Signals| Indicator | HGTY | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 63.69 |
| Support Level | $12.20 | $26.77 |
| Resistance Level | $12.89 | $30.22 |
| Average True Range (ATR) | 0.49 | 1.52 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 13.12 | 64.88 |
Price Performance
Historical ComparisonAbout HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.